Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications (2022)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.3389/fimmu.2022.816642
- Subjects: REPARAÇÃO DE DNA; IMUNOTERAPIA; NEOPLASIAS; FARMACOTERAPIA
- Keywords: DNA damage; PARP (poly(ADP-ribose); Cancer; Immune response; Immunotherapy; Polymerase
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Immunology
- ISSN: 1664-3224
- Volume/Número/Paginação/Ano: v. 13, art. 816642, p.1-10, 2022
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
WANDERLEY, Carlos Wagner de Souza et al. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, v. 13, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.816642. Acesso em: 30 mar. 2026. -
APA
Wanderley, C. W. de S., Correa, T. S., Scaranti, M., Cunha, F. de Q., & Barroso-Sousa, R. (2022). Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, 13, 1-10. doi:10.3389/fimmu.2022.816642 -
NLM
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2026 mar. 30 ] Available from: https://doi.org/10.3389/fimmu.2022.816642 -
Vancouver
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2026 mar. 30 ] Available from: https://doi.org/10.3389/fimmu.2022.816642 - Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Platelets fuel the inflammasome activation of innate immune cells
- Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation
- The endogenous cytokine profile and nerve fibre density in mouse ear Leishmania major-induced lesions related to nociceptive thresholds
- Effect of gedunin on acute articular inflammation and hypernociception in mice
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003153421.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
